1. Mazzon I, Corrado G, Masciullo V, Morricone D, Ferrandina G, Scambia G. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010; 93:1286–1289.
2. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009; 105:109.
3. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016; 27:16–41.
4. Schwarz JK, Beriwal S, Esthappan J, Erickson B, Feltmate C, Fyles A, et al. Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer. Brachytherapy. 2015; 14:587–599.
5. Modesitt SC, van Nagell JR Jr. The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet Gynecol Surv. 2005; 60:683–692.
6. Laframboise S, Milosevic M, Leyland N. Hysteroscopic endometrial resection and high-dose-rate brachytherapy: treatment of endometrial cancer in a medically compromised patient. Gynecol Oncol. 1999; 75:149–151.
7. Coon D, Beriwal S, Heron DE, Kelley JL, Edwards RP, Sukumvanich P, et al. High-dose-rate Rotte “Y” applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results. Int J Radiat Oncol Biol Phys. 2008; 71:779–783.
8. Kim JJ, Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med. 2010; 28:81–90.
9. Hawkes AL, Quinn M, Gebski V, Armes J, Brennan D, Janda M, et al. Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. Contemp Clin Trials. 2014; 39:14–21.
10. Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol. 2017; 28:e2.
11. Casadio P, Guasina F, Paradisi R, Leggieri C, Caprara G, Seracchioli R. Fertility-sparing treatment of endometrial cancer with initial infiltration of myometrium by resectoscopic surgery: a pilot study. Oncologist. 2018; 23:478–480.
12. Giampaolino P, Di Spiezio Sardo A, Mollo A, Raffone A, Travaglino A, Boccellino A, et al. Hysteroscopic endometrial focal resection followed by levonorgestrel intrauterine device insertion as a fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial cancer: a retrospective study. J Minim Invasive Gynecol. Forthcoming. 2018.
13. Vilos GA, Ettler HC, Edris F, Hollett-Caines J, Abu-Rafea B. Endometrioid adenocarcinoma treated by hysteroscopic endomyometrial resection. J Minim Invasive Gynecol. 2007; 14:119–122.
14. Boyd O, Jackson N. How is risk defined in high-risk surgical patient management? Crit Care. 2005; 9:390–396.
15. Murray LJ, Lilley J, Hawkins MA, Henry AM, Dickinson P, Sebag-Montefiore D. Pelvic re-irradiation using stereotactic ablative radiotherapy (SABR): a systematic review. Radiother Oncol. 2017; 125:213–222.
16. Podzielinski I, Randall ME, Breheny PJ, Escobar PF, Cohn DE, Quick AM, et al. Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma. Gynecol Oncol. 2012; 124:36–41.
18. van der Steen-Banasik E. Primary brachytherapy as a radical treatment for endometrial carcinoma. J Contemp Brachytherapy. 2014; 6:106–112.
19. Orbo A, Vereide A, Arnes M, Pettersen I, Straume B. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG. 2014; 121:477–486.
20. Vitale SG, Rossetti D, Tropea A, Biondi A, Laganà AS. Fertility sparing surgery for stage IA type I and G2 endometrial cancer in reproductive-aged patients: evidence-based approach and future perspectives. Updates Surg. 2017; 69:29–34.
21. Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol. 2005; 97:924–927.
22. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002; 186:651–657.
23. Baker J, Obermair A, Gebski V, Janda M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012; 125:263–270.
24. Vilos GA, Edris F, Al-Mubarak A, Ettler HC, Hollett-Caines J, Abu-Rafea B. Hysteroscopic surgery does not adversely affect the long-term prognosis of women with endometrial adenocarcinoma. J Minim Invasive Gynecol. 2007; 14:205–210.
25. Revel A, Tsafrir A, Anteby SO, Shushan A. Does hysteroscopy produce intraperitoneal spread of endometrial cancer cells? Obstet Gynecol Surv. 2004; 59:280–284.
26. Lurain JR, Rumsey NK, Schink JC, Wallemark CB, Chmiel JS. Prognostic significance of positive peritoneal cytology in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol. 1989; 74:175–179.
27. Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol. 1992; 46:145–149.